Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease

Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is almost exclusively effective in patients with activating EGFR mutations, and median time to progression in such patients is generally up to 12 months. Usually, treatment with EGFR-TKI is terminated when disease progression is c...

Full description

Bibliographic Details
Main Authors: Young Hak Kim, Akiko Fukuhara, Michiaki Mishima
Format: Article
Language:English
Published: Karger Publishers 2011-09-01
Series:Case Reports in Oncology
Subjects:
Epidermal growth factor receptor-tyrosine kinase inhibitor
Progressive disease
Non-small cell lung cancer
EGFR mutation
Acquired resistance
Continuation
Online Access:http://www.karger.com/Article/FullText/332758

Internet

http://www.karger.com/Article/FullText/332758

Similar Items